Evidence map›Paper›PMID 33835371›Full record

ArticleJournal of neuro-oncology2021

Dura promotes metastatic potential in prostate cancer through the CXCR2 pathway.

Michael J Strong, Sabrina Rocco, Russell Taichman, Gregory A Clines, Nicholas J Szerlip

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Michael J StrongDepartment of Neurosurgery, University of Michigan, 3552 Taubman Center, 1500 E. Medical Center Dr., Ann Arbor, MI, 48109, USA.ORCID http://orcid.org/0000-0001-9930-3578
Sabrina RoccoDepartment of Neurosurgery, University of Michigan, 3552 Taubman Center, 1500 E. Medical Center Dr., Ann Arbor, MI, 48109, USA.ORCID http://orcid.org/0000-0002-7822-072X
Russell TaichmanSchool of Dentistry, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID http://orcid.org/0000-0002-7890-0020
Gregory A ClinesDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0002-3755-7529
Nicholas J SzerlipDepartment of Neurosurgery, University of Michigan, 3552 Taubman Center, 1500 E. Medical Center Dr., Ann Arbor, MI, 48109, USA. nszerlip@med.umich.edu.ORCID http://orcid.org/0000-0003-1116-3422
University of Michigan · USUniversity of Alabama at Birmingham · US

Funding

Tumor microvesicle-mediated modulation of the bone microenvironmentP01CA093900 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PIENTA, KENNETH J. · 2004 to 2024
$29.6M
Engineering stem cells as diagnostic and therapeutic agents for glioblastomaR21NS107879 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CALINESCU, ANDA-ALEXANDRA · 2018 to 2019
$415k
NCI NIH HHS P01 CA093900NIH HHS P01CA093900NIH HHS R21NS107879
6 · The paper itself

Abstract

purposeSpinal metastases are common in cancer. This preferential migration/growth in the spine is not fully understood. Dura has been shown to affect the surrounding microenvironment and promote cancer growth. Here, we investigate the role of dural cytokines in promoting the metastatic potential of prostate cancer (PCa) and the involvement of the CXCR2 signaling pathway.

methodsThe role of dural conditioned media (DCM) in proliferation, migration and invasion of five PCa cell lines with various hormone sensitivities was assessed in the presence or absence of the CXCR2 inhibitor, SB225002. CXCR2 surface protein was examined by FACS. Cytokine levels were measured using a mouse cytokine array.

resultsWe observed high levels of cytokines produced by dura and within the vertebral body bone marrow, namely CXCL1 and CXCL2, that act on the CXCR2 receptor. All prostate cell lines treated with DCM demonstrated significant increase in growth, migration and invasion regardless of androgen sensitivity, except PC3, which did not significantly increase in invasiveness. When treated with SB225002, the growth response to DCM by cells expressing the highest levels of CXCR2 as measured by FACS (LNCaP and 22Rv1) was blunted. The increase in migration was significantly decreased in all lines in the presence of SB225002. Interestingly, the invasion increase seen with DCM was unchanged when these cells were treated with the CXCR2 inhibitor, except PC3 did demonstrate a significant decrease in invasion.

conclusionDCM enhances the metastatic potential of PCa with increased proliferation, migration and invasion. This phenomenon is partly mediated through the CXCR2 pathway.

Indexed as

Prostatic NeoplasmsCell Line, TumorCytokinesHumansMaleReceptors, Interleukin-8BSignal TransductionTumor MicroenvironmentCXCR2 protein, humanCytokinesReceptors, Interleukin-8BConditioned mediaCXCR2DuraMetastatic potentialProstate cancerSpine metastases

Identifiers

PMID33835371
OpenAlexW3151211953

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.